Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Anderson

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Glomerular Diseases|October 30, 2023
Developing an Edema Clinician-Reported Outcome Measure for Nephrotic SyndromeDebbie S Gipson, Maisha Pal, Hailey Desmond, et al.
Therapeutic Advances in Medical Oncology|September 29, 2022
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trialMaria-Pilar Barretina-Ginesta, Bradley J Monk, Sileny Han, et al.
Infection and Immunity|July 26, 2021
<i>Plasmodium</i> Preerythrocytic Vaccine Antigens Enhance Sterile Protection in Mice Induced by Circumsporozoite ProteinShaji Daniel, Alexander Pichugin, Holly Torano, et al.
Gynecologic Oncology|April 26, 2025
Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trialBenoit You, Charles Anderson, Sabrina Chiara Cecere, et al.
Alcohol, Clinical & Experimental Research|January 5, 2025
Impact of chronic ethanol consumption and SARS-COV-2 on the liver and intestine: A pilot dose-response study in miceSmita Ghare, Dennis Warner, Jeffrey Warner, et al.
The Journal of Clinical Investigation|February 9, 2021
Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not miceSara A Healy, Charles Anderson, Bruce J Swihart, et al.
Plos One|October 18, 2016
Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve AdultsKawsar R Talaat, Ruth D Ellis, Janet Hurd, et al.
Gynecologic Oncology|August 25, 2023
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancerSandro Pignata, Michael Bookman, Jalid Sehouli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 3, 2023
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical TrialCharles N Landen, Luciana Molinero, Habib Hamidi, et al.
Infection and Immunity|July 15, 2015
Reversible Conformational Change in the Plasmodium falciparum Circumsporozoite Protein Masks Its Adhesion DomainsRaul Herrera, Charles Anderson, Krishan Kumar, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Glomerular Diseases|October 30, 2023
Developing an Edema Clinician-Reported Outcome Measure for Nephrotic SyndromeDebbie S Gipson, Maisha Pal, Hailey Desmond, et al.
Therapeutic Advances in Medical Oncology|September 29, 2022
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trialMaria-Pilar Barretina-Ginesta, Bradley J Monk, Sileny Han, et al.
Infection and Immunity|July 26, 2021
<i>Plasmodium</i> Preerythrocytic Vaccine Antigens Enhance Sterile Protection in Mice Induced by Circumsporozoite ProteinShaji Daniel, Alexander Pichugin, Holly Torano, et al.
Gynecologic Oncology|April 26, 2025
Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trialBenoit You, Charles Anderson, Sabrina Chiara Cecere, et al.
Alcohol, Clinical & Experimental Research|January 5, 2025
Impact of chronic ethanol consumption and SARS-COV-2 on the liver and intestine: A pilot dose-response study in miceSmita Ghare, Dennis Warner, Jeffrey Warner, et al.
The Journal of Clinical Investigation|February 9, 2021
Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not miceSara A Healy, Charles Anderson, Bruce J Swihart, et al.
Plos One|October 18, 2016
Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve AdultsKawsar R Talaat, Ruth D Ellis, Janet Hurd, et al.
Gynecologic Oncology|August 25, 2023
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancerSandro Pignata, Michael Bookman, Jalid Sehouli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 3, 2023
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical TrialCharles N Landen, Luciana Molinero, Habib Hamidi, et al.
Infection and Immunity|July 15, 2015
Reversible Conformational Change in the Plasmodium falciparum Circumsporozoite Protein Masks Its Adhesion DomainsRaul Herrera, Charles Anderson, Krishan Kumar, et al.
Pageof 7